ClinicalTrials.gg

Prostatic Hyperplasia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 828 studies for Prostatic Hyperplasia across more than 10 countries. 179 are recruiting or about to start. 679 of them are mainly about Prostatic Hyperplasia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

ClinicalTrials.gov finds 886 studies for Prostatic Hyperplasia. How that becomes 826 here

This page counts the studies the registry files under Prostatic Hyperplasia, and those it files under no condition that list Prostatic Hyperplasiathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 886Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −4List Prostatic Hyperplasia as a condition, but the registry did not file them under itMost often written as “Prostatic Hyperplasia of the Medial Lobe” (1), “Benign Prostatic Hyperplasia With Outflow Obstruction” (1), and “Benign Prostatic Hyperplasia Postoperative Pain” (1). The registry filed them under other conditions only, most often Lower Urinary Tract Symptoms (3) and Urinary Retention (1).
  3. −56Match it another way41 name it in the title, 1 in a keyword, and 14 by a synonym or other text the search reads.
  4. 826The count on this page16 of them list Prostatic Hyperplasia in their own words; the registry filed them under no condition.

Status

Completed
456
Recruiting
102
Status unknown
91
Not yet recruiting
73
Terminated
40
Active, not recruiting
38

Phase

Phase 4
97
Phase 3
90
Phase 2
77
Phase 1
63
Early Phase 1
8

Where

United States
187
Egypt
79
Korea, Republic of
61
France
59
China
53
Canada
53

Who develops what

Add Prostatic Hyperplasia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 12 programs from 8 companies, 12 with this as their studies’ main aim; 3 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Yuhan, Chong Kun Dang Pharmaceutical and Ache Laboratorios Farmaceuticos here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TamsulosinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07134907 · Shanghai Huilun Pharmaceutical Co., Ltd. · Phase 4 · comparator · “Tamsolusin” · registered Aug 2025
  • NCT05551221 · xintian pharmaceutical · Phase 4 · comparator · “Tamsulosin” · registered Sep 2022
  • NCT05531344 · remd medical technology · Phase 3 · comparator · “Tamsulosin Hydrochloride Capsules” · registered Sep 2022
  • NCT04185441 · EMS · Phase 3 · comparator · “Omnic Ocas” · registered Dec 2019
  • NCT02827578 · ildong pharmaceutical · Phase 3 · background · “Tamsulosin” · registered Jul 2016
Boehringer Ingelheim23% of its industry studies33 studies

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
H077☆ Track1 live phase-3 study: NCT07146386Shanghai Huilun Pharmaceutical Co., Ltd.
Product DNN.65.21.005☆ Track1 live phase-3 study: NCT07270432Ache Laboratorios Farmaceuticos S.A.
FinasterideApproved: US☆ Track1 live phase-3 study: NCT07870759Il-Yang Pharm. Co., Ltd.

The 3 in phase 3 with the nearest primary completion, of 12 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.H077 · Shanghai Huilun Pharmaceutical Co., Ltd. · Phase 3 main aimNCT07146386 A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia — primary endpoint: changes in International Prostatism Symptom Score (IPSS) at 12 weeks from baseline · 728 enrolled
  • Apr 2027 est.Product DNN.65.21.005 · Ache Laboratorios Farmaceuticos S.A. · Phase 3 main aimNCT07270432 Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia — primary endpoint: Change in International Prostate Symptom Score (IPSS) · 218 enrolled
  • 31 Aug 2027 est.Finasteride · Il-Yang Pharm. Co., Ltd. · Phase 3 main aimNCT07870759 Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — primary endpoint: Total IPSS · 660 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Prostatic Hyperplasia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here 5-alpha reductase inhibitors 2 open · PDE5 inhibitors 2 open · Antimuscarinics 12

Coming up

73studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger. 7 (7%) take children under 18. 0 (0%) are for women only and 99 (97%) for men only; 7 (7%) take healthy volunteers.

Recruiting studies that take each age, of 102
AgeWomenMen
100 (0%)5 (5%)
181 (1%)41 (40%)
302 (2%)44 (43%)
402 (2%)56 (55%)
503 (3%)100 (98%)
653 (3%)101 (99%)
753 (3%)100 (98%)
853 (3%)85 (83%)

Across all 828 studies, recruiting or not: 9% stop at 75 or younger and 5% at 65; 8% take children; 0% are for women only and 96% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Prostatic Hyperplasia studies take

Of 34 phase 1 interventional studies under Prostatic Hyperplasia, half reached primary completion within 3 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 13 mo1–6 · 34 studies3 mo1–4 · 26 studies—
Phase 232 mo13–76 · 17 studies——
Phase 328 mo19–50 · 17 studies——
Phase 423 mo10–26 · 28 studies——
Interventional, no phase26 mo15–48 · 205 studies30 mo10–50 · 52 studies25 mo15–48 · 153 studies
Observational25 mo12–50 · 74 studies—33 mo10–50 · 59 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 828. Browse all 828 → or search them.